Ferring Pharmaceuticals, headquartered in Saint-Prex, Switzerland, has entered into a licensing agreement and initiated an early development agreement with Enteris BioPharma, a Boonton, New Jersey-headquartered biotechnology company that specializes in proprietary drug-delivery technologies, to use Enteris’ oral peptide and small-molecule delivery platform, Peptelligence, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

Under the agreement, Enteris will license to Ferring its oral drug-delivery technologies and provide clinical trial finished product as well receive milestones and royalties based on net sales of the developed product.

Source: Ferring